Use of surgery and carboplatin in feline malignant mammary gland neoplasms with advanced clinical staging

dc.contributor.authorCampos, Cecilia Bonolo de [UNESP]
dc.contributor.authorNunes, Fernanda Camargo
dc.contributor.authorLavalle, Gleidice Eunice
dc.contributor.authorCassali, Geovanni Dantas [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionUniversidade Federal de Minas Gerais (UFMG)
dc.date.accessioned2015-03-18T15:56:38Z
dc.date.available2015-03-18T15:56:38Z
dc.date.issued2014-09-01
dc.description.abstractBackground/Aim: Feline mammary carcinomas (FMCs) are characterized by poor prognosis and little progress has been made in extending patient survival. The aim of the study was to compare overall survival periods of FMCs submitted to different treatment protocols, including surgery and adjuvant chemotherapy. Materials and Methods: Analysis of conventional surgical excision alone or in association with adjuvant chemotherapy with carboplatin in sixteen cats diagnosed with stage III and grade II or III FMCs was performed. Results: Patients treated with surgery and chemotherapy presented a longer overall survival (OS) than those treated only with surgery, however, no statistical difference was observed when comparing both treatments (p=0.883). Conclusion: Therapeutic benefit of carboplatin remains invalidated for FMCs and further investigation regarding adjuvant therapies are warranted. Surgery remains as the gold treatment in FMCs.en
dc.description.affiliationSao Paulo State Univ FCAV UNESP, Sch Agr & Vet Sci, Postgrad Program Vet Med, Jaboticabal, Brazil
dc.description.affiliationFed Univ Minas Gerais UFMG, Biol Sci Inst ICB, Dept Gen Pathol, Lab Comparat Pathol, Belo Horizonte, MG, Brazil
dc.description.affiliationFed Univ Minas Gerais UFMG, Sch Vet, Vet Hosp, Dept Vet Clin & Surg, Belo Horizonte, MG, Brazil
dc.description.affiliationUnespSao Paulo State Univ FCAV UNESP, Sch Agr & Vet Sci, Postgrad Program Vet Med, Jaboticabal, Brazil
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG)
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.format.extent863-866
dc.identifierhttp://iv.iiarjournals.org/content/28/5/863.full
dc.identifier.citationIn Vivo. Athens: Int Inst Anticancer Research, v. 28, n. 5, p. 863-866, 2014.
dc.identifier.issn0258-851X
dc.identifier.urihttp://hdl.handle.net/11449/117651
dc.identifier.wosWOS:000341281900024
dc.language.isoeng
dc.publisherInt Inst Anticancer Research
dc.relation.ispartofIn Vivo
dc.relation.ispartofjcr1.116
dc.rights.accessRightsAcesso restrito
dc.sourceWeb of Science
dc.subjectFelineen
dc.subjectmammary glanden
dc.subjectneoplasmen
dc.subjectchemotherapyen
dc.subjectcarboplatinen
dc.titleUse of surgery and carboplatin in feline malignant mammary gland neoplasms with advanced clinical stagingen
dc.typeArtigo
dcterms.rightsHolderInt Inst Anticancer Research

Files

Collections